Clinical Trials Browser

Phase 2/3 × Recruiting × Standard of Care × Clear all

NCT07155187 2026-03-11

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT07005102 2026-01-23

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Phase 2/3 Recruiting

Neoplasms

NCT05833815 2024-08-13

Addition of Everolimus to Standard of Care in Carcinoma Gallbladder

Phase 2/3 Recruiting

Gastrointestinal

Gallbladder Neoplasms

NCT03548571 2024-04-03

DEN-STEM

Phase 2/3 Recruiting

Glioblastoma